Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Closed Solicitation Posted
- Solicitation number
- HT9402-24-Q-9402
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- San Antonio, Texas 78230, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Defense (DoD) Defense Health Agency is seeking quotes from pharmaceutical manufacturers for the DoD Uniform Formulary Blanket Purchase Agreement (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP). The quotes will be for newly approved drugs in the Pulmonary 2-Agents (Chronic Obstructive Pulmonary Disease subclass) and Sofdra - Antiperspirants drug classes, to be considered for placement on the DoD Uniform Formulary at the November 2024 Pharmacy and Therapeutics Committee meeting. The DoD will evaluate the relative clinical and cost effectiveness of the drugs, and manufacturers must submit quotes by August 8, 2024, along with responses to clinical questions. A pre-proposal teleconference is scheduled for July 24, 2024.
This is an unrestricted solicitation, with no set-aside designation. The DoD may award UF BPA and UF ADP agreements based on the Pharmacy and Therapeutics Committee's formulary placement decisions for the newly approved drugs. The place of performance is San Antonio, TX. The solicitation documents do not provide specific budget information or anticipated award values.
Notice text
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: November 2024: The following newly approved drugs will be reviewed:
a. Pulmonary 2-Agents - Subclass: Chronic Obstructive Pulmonary Disease
b. Sofdra - Antiperspirants - Subclass: N/A
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-24-Q-9402.
Pre-proposal teleconference is on July 24, 2024, details are stated in Part 2.5. Pre-proposal teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.
Files
| File | Type | Posted |
|---|---|---|
| A-3 NDC Price List FAQ NAD.pdf | ||
| A3 DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| A-3 RFQ HT9402-24-Q-9402 NAD.pdf | ||
| A-3 NDC Price List Ohtuvayre - Pulmonary-2 Agents - COPD.xlsx | XLSX spreadsheet | |
| A-3 NDC Price List Sofdra - Antiperspirants - NA.xlsx | XLSX spreadsheet |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity